Discover more insights into Anti Egfr Therapy 항 Egfr 요법

Keywords frequently search together with Anti Egfr Therapy 항 Egfr 요법

Narrow sentence examples with built-in keyword filters

Anti Egfr Therapy sentence examples within metastatic colorectal cancer



Efficacy of an anti-EGFR after ctDNA conversion from mutated RAS status of metastatic colorectal cancer: Results of a pilot study.


Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.


Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.



Abstract 2373: Expression of exosomal let-7g in biofluids and outcome in colon cancer patient treated with anti-EGFR therapy



Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice


More Anti Egfr Therapy 항 Egfr 요법 sentence examples
10.1200/JCO.2021.39.15_SUPPL.E15503

Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.



Abstract 1099: Resistance to anti-EGFR therapy can spread horizontally among cancer cells



Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer.



Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer



Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling



The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis



HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer



Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.



Перспективы анализа циркулирующей опухолевой ДНК для нужд практической онкологии: достижения и нерешённые проблемы



Implications of Pathological Findings in Cytoreductive Surgery Specimens on Treatment of Colorectal Peritoneal Metastases- Results of a Prospective Multi-Centric Study.



Circulating tumor DNA in identifying resistant subclones post EGFR blockade: Implications for EGFR rechallenge.



Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review


More Anti Egfr Therapy 항 Egfr 요법 sentence examples
10.1200/JCO.2021.39.15_SUPPL.E15589

Rationale for the utilization of biological targeted agents (bTAs) in the treatment of metastatic colorectal cancer (mCRC), single tertiary cancer center experience.



Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.



Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck



PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation



FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.



Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).



Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma



Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer



Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures


More Anti Egfr Therapy 항 Egfr 요법 sentence examples
10.1200/JCO.2021.39.15_SUPPL.E18626

COVID-19 related outcomes for hospitalized patients (pts) with solid malignancies (SM).



Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.



A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.



Clinical significance of primary tumour location in colorectal cancer — a review



Detection of therapeutically relevant and concomitant rare somatic variants in colorectal cancer.



Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer



Mechanisms of Cetuximab Resistance and How to Overcome It



RAS amplification as a negative predictor of benefit from anti-EGFR containing therapy regimens in metastatic colorectal cancer.



Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).



Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).



Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.



Colorectal cancer progression is potently reduced by a glucose-free, high-protein diet: comparison to anti-EGFR therapy



Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors



Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy



Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer



REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer



Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.



Clinical significance of IDH1, EGFR, p53 and MIB1 in Astrocytoma Patients


Learn more from Anti Egfr Therapy 항 Egfr 요법

Anti Egfr Therapy 항 Egfr 요법


Anti Egfr Therapy 항 Egfr 요법
Encyclopedia 백과사전